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Abstract
Background: Genomic instability plays an important role in human cancers. We previously characterized genomic
instability in esophageal squamous cell carcinomas (ESCC) in terms of loss of heterozygosity (LOH) and copy
number (CN) changes in tumors using the Affymetrix GeneChip Human Mapping 500K array in 30 cases from a
high-risk region of China. In the current study we focused on copy number neutral (CN = 2) LOH (CNNLOH) and
its relation to gene expression in ESCC.
Results: Overall we found that 70% of all LOH observed was CNNLOH. Ninety percent of ESCCs showed CNNLOH
(median frequency in cases = 60%) and this was the most common type of LOH in two-thirds of cases. CNNLOH
occurred on all 39 autosomal chromosome arms, with highest frequencies on 19p (100%), 5p (96%), 2p (95%), and
20q (95%). In contrast, LOH with CN loss represented 19% of all LOH, occurred in just half of ESCCs (median
frequency in cases = 0%), and was most frequent on 3p (56%), 5q (47%), and 21q (41%). LOH with CN gain was
11% of all LOH, occurred in 93% of ESCCs (median frequency in cases = 13%), and was most common on 20p
(82%), 8q (74%), and 3q (42%). To examine the effect of genomic instability on gene expression, we evaluated RNA
profiles from 17 pairs of matched normal and tumor samples (a subset of the 30 ESCCs) using Affymetrix U133A
2.0 arrays. In CN neutral regions, expression of 168 genes (containing 1976 SNPs) differed significantly in tumors
with LOH versus tumors without LOH, including 101 genes that were up-regulated and 67 that were down-
regulated.
Conclusion: Our results indicate that CNNLOH has a profound impact on gene expression in ESCC, which in turn
may affect tumor development.
Background
Genomic instability is important for cancer development
and can manifest as copy number (CN) gain or loss as
well as loss of heterozygosity (LOH). Copy number neu-
tral LOH (CNNLOH) has been observed in tumors fol-
lowing the widespread application of SNP array
technology [1,2]. CNNLOH is common in many tumor
types, including basal cell carcinoma [3], acute myeloid
leukemia [4,5], medulloblastoma [6], melanoma [7], folli-
cular lymphoma [8], colorectal cancers [9-11], glioblas-
toma [12,13], cutaneous squamous cell carcinomas [14],
acute promyelocytic leukemia [15], acute lymphoblastic
leukemia [16], ovarian tumor [17], and esophageal ade-
nocarcinoma [18], and has recently been reviewed for
myeloid malignancies [19]. CNNLOH is thought to
result from mitotic recombination or nondisjunction in
somatic tumor cells [3]. However, the distribution of
complex DNA alterations and its relation to gene
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ESCC.
ESCC is a common malignancy worldwide and one of
the most common cancers in the Chinese population;
Shanxi Province in north central China has some of the
highest esophageal cancer rates in the world [20,21]. Pre-
viously, we identified several regions of LOH and CN
alteration in ESCC using microsatellite markers and low-
and high-density SNP arrays [22-27], where the majority
of ESCC patients from this high-risk population were
found to have high genomic instability and high frequency
of LOH on several chromosome arms. However, we have
not found causal mutations in candidate genes within the
LOH regions identified. For example, 82% of 56 ESCCs
showed LOH when tested with four microsatellite markers
flanking ANXA1 (9q11-q21), but no somatic mutations
were detected in these patients [28]. Another example is
BRCA2, which also showed frequent LOH in ESCC (57%
for D13S260, 83% for D13S767), but only infrequent
somatic mutations in these cancer patients (2/56, 3.5%)
[29,30]. Contrary to expectation, expression of BRCA2 was
often increased (unpublished data).
In the present study, we analyzed DNA from 30 micro-
dissected ESCC tumors, adjacent normal tissue, and
blood DNA from the same patient using the Affymetrix
5 0 0 KS N Pa r r a yt oi d e n t i f yt he distribution of complex
DNA alterations, including CNNLOH, and we related
CNNLOH to expression of the genes affected as assessed
with the Affymetrix U133A 2.0 array in these patients.
Methods
Case selection
This study was approved by the Institutional Review
Boards of the Shanxi Cancer Hospital and the US
National Cancer Institute (NCI). Cases diagnosed with
ESCC between 1998 and 2001 in the Shanxi Cancer
Hospital in Taiyuan, Shanxi Province, PR China, and
considered candidates for curative surgical resection
were identified and recruited to participate in this study.
None of the cases had prior therapy and Shanxi was the
ancestral home for all. After obtaining informed con-
sent, cases were interviewed to obtain information on
demographics, cancer risk factors (eg, smoking, alcohol
drinking, and detailed family history of cancer), and
clinical information. The cases evaluated here were part
of a larger case-control study of upper gastrointestinal
cancers conducted in Shanxi Province [31-33].
Biological specimen collection and processing
Venous blood (10 ml) was taken from each case prior to
s u r g e r ya n dg e r m - l i n eD N Af r o mw h o l eb l o o dw a s
extracted and purified using the standard phenol/chloro-
form method.
Tumor and adjacent normal tissues were dissected at
the time of surgery and stored in liquid nitrogen until
used. One 5-micron section was H&E stained and
reviewed by a pathologist from the NCI to guide the
micro-dissection. Five to ten consecutive 8-micron sec-
tions were cut from fresh frozen tumor and adjacent
normal tissues. Tumor and normal cells were manually
micro-dissected under light microscopy. DNA was
extracted from micro-dissected tumor as previously
described [34] using the protocol from the Puregene
DNA Purification Tissue Kit (Gentra Systems, Inc., Min-
neapolis, MN). RNA was extracted from 17 of these
micro-dissected tumor and matched normal tissue pairs
using the protocol from the PureLink Micro-to-Midi
Total RNA Purification System (Catalog number 12183-
018, Invitrogen, Carlsbad, CA). RNA quality and quantity
were determined using the RNA 6000 Labchip/Agilent
2100 Bioanalyzer (Agilent Technologies, Germantown,
MD). The same tissue blocks were used for extraction of
both DNA and RNA for each case studied.
Target preparation for GeneChip Human Mapping 500 K
array set
The Affymetrix GeneChip Human Mapping 500 K array
set contains ~262,000 (Nsp I array) and ~238,000 (Sty I
array) SNPs (mean probe spacing = 5.8 Kb, mean het-
erozygosity = 27%). A detailed gene chip protocol can
be found at http://www.affymetrix.com/support/down-
loads/manuals/500k_assay_manual.pdf.
Experiments were conducted according to the proto-
col (GeneChip Mapping Assa ym a n u a l )s u p p l i e db y
A f f y m e t r i x ,I n c .( S a n t aC l a r a ,C A ) .G e n o t y p ec a l l sw e r e
generated by GTYPE v 4.0 software (Affymetrix). Germ-
line, tumor and adjacent normal DNA from each case
were run together in parallel in the same experiment (ie,
same batch, same day). The GEO accession numbers for
these array data are GSE15526 and GSE20347.
Probe preparation and hybridization for Human Genome
U133A 2.0 array
The Affymetrix Human Genome U133A 2.0 array is a
single array used to interrogate expression of 14,500
well-characterized human genes. Array experiments
were performed using 1-5 μg total RNA each. We fol-
lowed the protocol provided by the manufacturer to
carry out reverse transcription, labeling, and
hybridization.
GeneChip 500 K array data analysis
Probe intensity data from Affymetrix 500 K SNP arrays
were used to identify DNA alterations in the present
study. To avoid gender-related issues, SNPs mapped to
either the X or Y chromosome were excluded.
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isons of either adjacent normal to germ-line DNA or
tumor to germ-line DNA. Microarray data were first
normalized using the gtype-probe set-genotype package
included in Affymetrix Power Tools version 1.85. Each
tumor sample was individually normalized via the
BRLMM algorithm along with 99 blood samples. These
blood samples were obtained from the 30 ESCC cases
evaluated in the present study plus 69 healthy controls
(age-, sex-, and region-matched to cases) who were all
part of a larger case-control study of upper gastrointest-
inal cancers conducted in Shanxi Province (as noted
above). Paired CN analysis was then performed on each
sample using the Affymetrix Power Tools paired-copy-
number workflow, which implements the Affymetrix
Copy Number Analysis Tool (CNAT) algorithm. DNA
obtained from the blood of each case served as the nor-
mal control; a sliding window of 100 kb was chosen to
optimize the identification of extended regions of CN
alteration (see http://www.affymetrix.com/support/tech-
nical/whitepapers/cnat_4_algorithm_whitepaper.pdf).
The output of the CNAT program is CN state rather
than an absolute CN prediction: normal CN corre-
sponds to a state of 2; zero and 1 correspond to CN
loss; and states 3 and 4 correspond to CN gain.
In the present study, we modified the method for
identifying LOH used in our previous studies [26,27].
Here, LOH was determined using the Affymetrix Power
Tools copynumber-pipeline program paired-LOH work-
flow. Input was *.CHP files generated with the gtype-
probeset-genotype package as described above. Matched
blood DNA served as the reference for LOH analysis for
each tumor and normal adjacent sample.
Combination of LOH and CN alterations
We defined six combinations of copy number state and
LOH status. LOH positive loci may have CN loss (CN
≤ 1), be CN neutral (CNNLOH, CN = 2) or show CN
gain (CN ≥ 3); Likewise, LOH negative loci may show
CN loss, gain, or neutrality. LOH and CN segments
for each tumor were defined independently for each
sample as contiguous blocks of informative SNPs that
possessed the same LOH and CN state. Endpoints of
LOH/CN segments were defined by informative SNPs.
Some uninformative SNPs were located between these
LOH/CN segments; we considered these SNPs to have
an undefined LOH/CN state (see Additional file 1/Fig-
ure S1). Segment sizes were empirically observed from
the data.
Comparison of CN status in DNA from blood versus
micro-dissected adjacent normal tissue
DNA isolated from normal adjacent tissue is frequently
used as a control in microarray experiments. In the
present study we used DNA isolated from peripheral
blood. We expected peripheral blood DNA to be a
superior control for two reasons: first, unlike adjacent
normal tissue, it is does not run the risk of being con-
taminated with tumor cells; second, adjacent normal tis-
sue may actually be precancerous and contain genetic
lesions. To examine whether blood DNA and adjacent
normal esophageal DNA were equivalent controls, we
compared copy number state calls for blood and normal
adjacent from each of the 30 ESCC patients. We found
that the two controls were equivalent: 99.29% to 99.99%
of all copy number calls were identical. Overall, 99.96%
of SNPs in blood and 99.93% in normal adjacent tissue
were CN = 2 state.
Human Genome U133A 2.0 array data analysis and
relation between CNNLOH and mRNA expression
The Robust Multiarray Average (RMA) algorithm
[35,36] implemented in Bioconductor in R http://www.
bioconductor.org was used for background correction
and normalization across all samples. For each sample
log2 fold changes in gene expression were calculated by
subtracting the adjacent normal RMA value from the
corresponding tumor RMA value.
To determine whether any gene showed a difference
in the tumor versus normal gene expression fold change
that was dependent on LOH state, we performed the
following steps: (i) First, genes assayed by the U133A
microarray were mapped onto each LOHCN segment of
each sample. Map locations of genes were taken from
the Affymetrix version na29 microarray annotation file.
Note that probe sets from the same gene may have dif-
ferent reference sequences which differ in their chromo-
somal locations. Also, not every gene will map to every
sample - in a particular sample, a gene may map to a
gap between LOHCN regions. (ii) Next, we identified
genes for which at least two of the 17 ESCC samples
with expression data were LOH negative and at least
two samples were LOH positive. (iii) We then per-
formed two-sided unpaired t-tests comparing the log2
fold changes for a probe set in LOH positive and LOH
negative samples. A P-value < 0.01 was considered sig-
nificant. (iv) Finally, SNPs on the 500 K microarray
were mapped to the reference sequence for each expres-
sion probe set. Since probe sets from the same gene
m a yh a v ed i f f e r e n tr e f e r e n c es e q u e n c e s ,t h e ym a yd i f f e r
in the number of SNPs assigned to them (Additional file
2/Figure S2).
Results
I nt h ep r e s e n ts t u d yw ed e t e r m i n e dc o p yn u m b e ra n d
loss of heterozygosity (LOH) status in DNA isolated
from germ-line and micro-dissected tumor and matched
adjacent normal samples from 30 ESCC patients using
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call rate was 96% (89-99%): the 250 K Nsp I array was
96% (90-98%) and 250 K Sty I array was 95% (89-99%).
Genotype call rates were similar for all three tissue
types examined. We first analyzed whether copy num-
bers were similar between DNAs from the two normal
tissues: germ-line (blood) and micro-dissected adjacent
normal samples. Our analysis indicated that DNA CN
values were similar between the two normal tissues
(Additional file 3 - Table S1), as expected. Our results
indicate that germ-line DNA can be used as a normal
control in studies of CN alteration; it is more readily
available than matched adjacent normal tissue.
Complex DNA alterations in ESCC
The distribution of DNA alterations in each of the 30
ESCC cases is summarized in Table 1 (with LOH) and in
Additional file 4/Table S2 (without LOH). We divided
genomic regions into three groups based on CN states:
CN loss, neutral, and gain. We found that 50%, 90%, and
93% of cases showed LOH in the CN loss, neutral, and
gain groups, respectively (Table 1). For each chromo-
some, we also calculated the percentage of SNPs involved
in LOH for each group. They ranged between 20-57%, 7-
100%, and 2-100% for the CN loss, neutral, and gain
groups, respectively (Table 1). Our results suggest that
LOH with CN neutral or gain are common phenomena
Table 1 LOH by copy number in ESCC cases by individual case (N = 30)
Case ID Total no. informative
SNPs with LOH
No. informative SNPs
with LOH and CN = 1 (fraction)
No. informative SNPs with
LOH and CN = 2 (fraction)
No. informative SNPs with
LOH and CN = 3 or 4 (fraction)
*1 31,808 2,260 (0.07) 26,801 (0.84) 2,747 (0.09)
2 368 0 (0) 205 (0.56) 163 (0.44)
3 377 0 (0) 139 (0.37) 238 (0.63)
*4 36,175 2,093 (0.06) 27,655 (0.76) 6,427 (0.18)
*5 24 0 (0) 0 (0) 24 (1.00)
*6 14,751 210 (0.01) 12,661 (0.86) 1,880 (0.13)
*7 3,559 0 (0) 2,905 (0.82) 654 (0.18)
*8 2,408 4 (0) 2,217 (0.92) 187 (0.08)
*9 593 1 (0) 266 (0.45) 326 (0.55)
10 17,546 1,075 (0.06) 12,087 (0.69) 4,384 (0.25)
11 78,159 3,678 (0.05) 67,726 (0.87) 6,755 (0.09)
12 41 0 (0) 0 (0) 41 (1.00)
*13 6,113 209 (0.03) 5,154 (0.84) 750 (0.12)
14 13,498 4,084 (0.30) 9,190 (0.68) 224 (0.02)
15 3 0 (0) 3 (1.00) 0 (0)
16 1431 0 (0) 54 (0.04) 1,377 (0.96)
17 16,934 5,732 (0.34) 10,842 (0.64) 360 (0.02)
18 2,107 0 (0) 1,553 (0.74) 554 (0.26)
*19 0 0 (0) 0 (0) 0 (0)
*20 527 0 (0) 137 (0.26) 390 (0.74)
*21 19,954 62 (0) 16,332 (0.82) 3,560 (0.18)
*22 11,180 4,410 (0.39) 6,357 (0.57) 413 (0.04)
*23 14,523 5,939 (0.41) 5,953 (0.41) 2,631 (0.18)
24 15,773 5,672 (0.36) 9,354 (0.59) 747 (0.05)
*25 23,005 20 (0) 17,114 (0.74) 5,871 (0.26)
*26 37,691 21,495 (0.57) 15,229 (0.40) 967 (0.03)
27 12,120 4,500 (0.37) 6,299 (0.52) 1,321 (0.11)
28 494 0 (0) 37 (0.07) 457 (0.93)
*29 18,222 444 (0.02) 15,400 (0.85) 2,378 (0.13)
*30 42,499 16,432 (0.39) 25,394 (0.60) 673 (0.02)
No. cases with SNP LOH fraction = 0 15 3 2
Range (fraction SNPs with LOH) 0-0.57 0-1.00 0-1.00
Median (fraction SNPs with LOH) 0.00 0.60 0.13
Global average (fraction SNPs with LOH) 0.19 0.70 0.11
*Case also examined with Affymetrix U133A 2.0 chip.
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percent of SNPs in each CN state; averages were 5%,
84%, and 11% for CN loss, neutral, and gain, respectively.
The distribution of the six types of DNA alterations for
all 30 cases by chromosome arm is shown in Table 2
(with LOH) and Additional file 5/Table S3 (without
LOH). CNNLOH was observed on all chromosome arms,
but most frequently on 19p (100%), 5p (96%), 2p (95%),
and 20q (95%). The highest frequencies of LOH with CN
loss (CN = 1) were found on 3p (56%), 5q (47%), and 21q
(41%); relatively high frequencies were also seen on 18q
(31%), 11q (29%), 1p (28%), 19q (27%), and 11p (25%).
LOH with CN gain was most common on 20p (82%), 8q
(74%) and 3q (42%) (Table 2 and Figure 1). Taken
Table 2 LOH by copy number in ESCC cases by chromosomal arm (N = 30 cases)
Chromosomal
arm
Total no. informative
SNPs with LOH
No. informative SNPs with
LOH and CN = 1 (fraction)
No. informative SNPs with
LOH and CN = 2 (fraction)
No. informative SNPs with LOH
and CN = 3 or 4 (fraction)
1p 10,576 2,930 (0.28) 6,522 (0.62) 1,124 (0.11)
1q 8,366 459 (0.05) 7,674 (0.92) 233 (0.03)
2p 11,321 371 (0.03) 10,770 (0.95) 180 (0.02)
2q 23,115 3,015 (0.13) 18,939 (0.82) 1,161 (0.05)
3p 27,593 15,335 (0.56) 12,064 (0.44) 194 (0.01)
3q 7,256 41 (0.01) 4,168 (0.57) 3,047 (0.42)
4p 12,223 4,771 (0.39) 7,452 (0.61) 0 (0)
4q 28,105 9,142 (0.33) 17,905 (0.64) 1,958 (0.04)
5p 1,315 0 (0) 1,259 (0.96) 56 (0.04)
5q 16,537 7,744 (0.47) 8,777 (0.53) 16 (0)
6p 5,622 342 (0.06) 4,870 (0.87) 410 (0.07)
6q 3,365 165 (0.05) 2,773 (0.82) 427 (0.13)
7p 7,389 9 (0) 5,491 (0.74) 1,889 (0.26)
7q 8,001 151 (0.02) 6,452 (0.74) 1,398 (0.17)
8p 8,803 1,580 (0.18) 6,234 (0.71) 989 (0.11)
8q 17,321 47 (0) 4,633 (0.27) 12,641 (0.74)
9p 18,292 2,772 (0.15) 13,333 (0.73) 2,187 (0.12)
9q 31,400 1,965 (0.06) 27,212 (0.87) 2,223 (0.07)
10p 2,739 472 (0.17) 2,063 (0.75) 204 (0.07)
10q 14,651 1,728 (0.12) 12,075 (0.82) 848 (0.06)
11p 9,391 2,367 (0.25) 6,902 (0.73) 122 (0.01)
11q 17,377 5,116 (0.29) 10,422 (0.60) 1,839 (0.11)
12p 5,229 156 (0.03) 3,251 (0.62) 1,822 (0.34)
12q 6,794 67 (0.01) 5,980 (0.88) 747 (0.11)
13q 35,648 5,897 (0.17) 25,964 (0.73) 3,787 (0.11)
14q 10,931 1,484 (0.14) 7,446 (0.68) 2,001 (0.18)
15q 10,194 685 (0.07) 8,313 (0.82) 1,196 (0.12)
16p 1,395 111 (0.08) 1,284 (0.92) 0 (0)
16q 3,127 1 (0) 2,832 (0.91) 294 (0.09)
17p 7,719 324 (0.04) 6,939 (0.90) 456 (0.06)
17q 16,328 38 (0) 14,754 (0.90) 1,536 (0.09)
18p 2,596 488 (0.19) 1,147 (0.44) 961 (0.37)
18q 9,978 3,108 (0.31) 6,838 (0.69) 32 (0)
19p 1,069 1 (0) 1,065 (1.00) 3 (0)
19q 3,505 932 (0.27) 2,482 (0.71) 91 (0.03)
20p 1,278 0 (0) 229 (0.18) 1,049 (0.82)
20q 1,773 60 (0.03) 1,677 (0.95) 36 (0.02)
21q 9,444 3,825 (0.41) 5,599 (0.59) 20 (0)
22q 4,177 621 (0.15) 3,274 (0.80) 222 (0.05)
Range (fraction SNPs with LOH) 0-0.56 0.18-1.00 0-0.82
Median (fraction SNPs with LOH) 0.05 0.71 0.05
Global average (fraction SNPs with LOH) 0.19 0.70 0.11
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gain were much more frequent than LOH with CN loss
on every chromosome arm but one (ie, 3p).
Results of CN alterations in non-LOH group by chro-
mosome arms are summarized in Additional file 5/
Table S3. Briefly, a frequency of CN loss ≥ 10% was
observed on eight chromosome arms (3p, 4p, 4q, 5q, 8p,
9p, 11q, and 13q). A frequency of CN gain ≥ 10% was
observed on 13 chromosome arms (1q, 2p, 2q 3q, 5p,
7p, 7q, 8q, 12p, 14q, 18p, 20p, and 20q).
Relation between genomic alterations and gene
expression
The average present call rate on the Human Genome
U133A array was 53% (range 51- 61%) for the 34 chips
from the 17 sample pairs with sufficient tissue for RNA
isolation and testing. To investigate the relation between
LOH/CNV and gene expression levels, we intersected
genes on the Affymetrix U133A chip with SNPs on the
500 K SNP array. SNPs that mapped within genes are
summarized in Additional file 6/Table S4 and include
169,687 SNPs within 12,225 genes.
We were interested in identifying differentially-
expressed genes between LOH and non-LOH groups in
genes that were CN neutral. A total of 4,572 genes quali-
fied for this analysis (see Methods). Among these genes,
168 genes showed significant differences in expression
between tumors with and without LOH (P < 0.01) (Addi-
tional file 7/Table S5). Based on chance alone (at the P <
0.01 level), differences in only 45 genes would be
Figure 1 Patterns of loss of heterozygosity and copy number variation in 30 ESCC samples for chromosome 3. Each row (numbered 1 -
30) represents an individual ESCC sample. Circles indicate the positions of SNPs showing LOH. SNP positions are color coded as follows: black
indicates copy number neutral LOH; blue indicates LOH accompanied by copy number reduction; red indicates LOH with copy number gain.
An ideogram of the chromosome is at the bottom of the figure.
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Page 6 of 11Table 3 Comparison of gene expression in copy number neutral (CNN) genes with LOH and without LOH (normal) (N =
46 genes significantly differentially-expressed 2-fold or greater)*
Gene
name
Cytoband Probeset on
U133A array
No. cases
with LOH
No. cases
without LOH
No.
SNPs
Fold change
CNN with LOH
Fold change CNN
without LOH
T-test P-value
Genes where expression level of CNN with LOH is less than CNN without LOH (N = 28 genes)
ADK chr10q22|
10q11-q24
204120_s_at 2 13 46 0.404 0.606 3.138 8.559E-03
ADK chr10q22|
10q11-q24
204119_s_at 2 13 46 0.411 0.619 3.195 7.278E-03
AIM1L chr1p36.11 220289_s_at 2 15 6 0.093 0.201 3.548 4.812E-03
APOL6 chr22q12.3 219716_at 2 5 4 0.467 0.894 4.659 9.543E-03
ATP6V0E1 chr5q35.2 201171_at 2 12 5 0.375 0.669 3.234 9.843E-03
ATP6V0E1 chr5q35.2 200096_s_at 2 12 5 0.480 0.872 4.445 5.699E-03
BACH1 chr21q22.11 204194_at 2 12 9 0.498 0.738 3.970 2.098E-03
BTG2 chr1q32 201236_s_at 2 14 1 0.460 0.986 4.095 1.183E-03
CD2 chr1p13.1 205831_at 2 14 1 0.324 0.628 3.462 9.221E-03
CEACAM6 chr19q13.2 211657_at 2 13 3 0.007 0.100 4.779 7.023E-03
CRAT chr9q34.1 209522_s_at 7 8 1 0.293 0.567 3.169 7.495E-03
CSDE1 chr1p22 202646_s_at 2 14 3 0.343 0.895 7.835 7.590E-05
CYP4F3 chr19p13.2 206515_at 2 13 136 0.065 0.307 3.329 5.631E-03
DIO2 chr14q24.2-
q24.3
203699_s_at 2 11 4 0.072 0.127 3.565 6.175E-03
DIO2 chr14q24.2-
q24.3
203700_s_at 2 11 4 0.168 0.280 3.697 3.752E-03
EIF4EBP2 chr10q21-
q22
208770_s_at 2 14 1 0.452 0.657 6.300 2.692E-05
FAS chr10q24.1 216252_x_at 2 13 8 0.412 0.648 3.058 9.883E-03
HERC6 chr4q22.1 219352_at 3 9 1 0.105 0.538 5.769 2.901E-04
ICAM3 chr19p13.3-
p13.2
204949_at 2 13 2 0.356 0.602 3.478 4.342E-03
IL1RN chr2q14.2 212659_s_at 2 12 13 0.073 0.142 3.256 7.793E-03
NADSYN1 chr11q13.4 218840_s_at 2 8 10 0.448 0.649 3.399 9.384E-03
NHP2 chr5q35.3 216583_x_at 2 10 1 0.497 0.774 4.091 2.584E-03
PDCD4 chr10q24 202730_s_at 2 12 4 0.212 0.363 4.483 9.256E-04
PPP1R13L chr19q13.32 218849_s_at 3 13 1 0.190 0.487 5.016 5.018E-04
RIPK4 chr21q22.3 221215_s_at 5 10 7 0.217 0.454 3.614 3.658E-03
SKAP2 chr7p21-p15 216899_s_at 2 10 12 0.293 0.615 4.165 1.973E-03
SKAP2 chr7p21-p15 204361_s_at 2 10 43 0.359 0.665 4.384 1.591E-03
SLC6A1 chr3p25-p24 205152_at 2 8 6 0.158 0.438 5.044 2.481E-03
STK39 chr2q24.3 202786_at 2 12 86 0.151 0.290 3.363 6.327E-03
SYNPO2L chr10q22.2 219804_at 3 13 1 0.063 0.345 6.925 8.703E-06
TGM5 chr15q15.2 207911_s_at 2 13 8 0.382 0.517 3.496 4.389E-03
ZNF91 chr19p13.1-
p12
206059_at 2 10 5 0.026 0.551 9.054 6.430E-04
Genes where expression level of CNN with LOH is greater than CNN without LOH (N = 18 genes)
ACVR1 chr2q23-q24 203935_at 2 12 13 3.480 1.751 -4.533 7.869E-04
ASPN chr9q22 219087_at 5 10 2 10.594 2.679 -3.792 2.667E-03
BUB1 chr2q14 209642_at 2 12 2 8.571 4.010 -3.922 2.170E-03
CALU chr7q32.1 200757_s_at 2 12 7 3.467 1.830 -4.612 7.505E-04
CALU chr7q32.1 200755_s_at 2 12 7 3.899 1.981 -3.903 2.269E-03
CAMSAP1L1 chr1q32.1 212765_at 2 13 3 3.000 1.357 -6.288 1.629E-03
CENPF chr1q32-q41 209172_s_at 2 14 10 5.481 2.643 -5.909 3.926E-05
CSNK1E chr22q13.1 202332_at 2 3 4 2.933 1.157 -7.434 9.278E-03
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Page 7 of 11expected, therefore, expression differences were observed
in over three times as many genes as expected. One hun-
dred and one (60%) of the 168 genes showed lower
expression levels in CNNLOH than in the normal group
(ie, CNN, no LOH), whereas 67 genes (40%) showed
higher expression levels in CNNLOH (Additional file 7/
Table S5). Twenty-eight of the 101 down-regulated genes
(32 probes) and 18 of the 67 up-regulated genes (19
probes) showed expression differences ≥ 2-fold (Table 3).
These findings suggest that in the CN neutral state, LOH
can affect gene expression.
We also compared expression of genes with LOH versus
no LOH in CN loss genes. We identified six of 600
genes which showed significantly different expression
between the LOH groups. All six genes showed
increased expression in tumors with LOH (Table 4a).
Finally, we compared gene expression in the CN gain
state between tumors with and without LOH. We
found that six of 354 genes showed significant differ-
ences in expression between the two groups, including
two down-regulated and four up-regulated genes
(Table 4b).
Discussion
We characterized ESCC tumors for complex DNA
alterations - LOH and CNV - and related these genomic
alterations to gene expression. To our knowledge, this is
the first report to comprehensively address the distribu-
tion of complex DNA alterations in ESCC and its rela-
tion to gene expression on a genome-wide scale.
Ninety percent of cases showed CNNLOH in their
tumors and, over all cases, CNNLOH was found on
Table 3: Comparison of gene expression in copy number neutral (CNN) genes with LOH and without LOH (normal) (N
= 46 genes significantly differentially-expressed 2-fold or greater)* (Continued)
FAM13A chr4q22.1 202973_x_at 3 10 14 2.756 1.149 -3.508 6.115E-03
FHL2 chr2q12-q14 202949_s_at 2 14 15 3.159 1.244 -4.697 4.097E-04
GSR chr8p21.1 205770_at 3 10 8 2.505 1.222 -3.701 4.824E-03
ITGA6 chr2q31.1 201656_at 2 11 21 4.038 2.400 -3.519 4.820E-03
KIF14 chr1q32.1 206364_at 2 13 6 11.027 3.578 -8.257 2.071E-06
NCAPH chr2q11.2 212949_at 2 11 2 3.643 1.943 -5.087 4.450E-04
NRP2 chr2q33.3 214632_at 3 11 29 2.161 1.257 -3.500 9.276E-03
RBM28 chr7q32.1 218593_at 2 11 9 2.210 1.555 -3.976 2.370E-03
SMAD5 chr5q31 205187_at 2 12 3 2.208 0.829 -10.692 3.171E-07
STEAP3 chr2q14.2 218424_s_at 2 14 12 2.707 1.207 -6.922 9.985E-06
TGS1 chr8q11 219231_at 2 8 1 2.533 1.656 -3.495 8.601E-03
*Sorted alphabetically by gene name.
Table 4 Comparison of gene expression in copy number loss/gain genes with LOH and without LOH*
Gene
name
Cytoband Probeset on
U133A array
No. cases
with LOH
No. cases
without LOH
No.
SNPs
Fold change
with LOH
Fold change
without LOH
T-test P-value
Table 4.a.: Genes/probes with CN loss (CN = 1)
ATXN7 chr3p21.1-p12 204516_at 4 2 10 0.574 0.258 -8.233 1.333E-03
CTDSPL chr3p21.3 213597_s_at 3 3 13 0.997 0.890 -5.414 8.188E-03
F2R chr5q13 203989_x_at 3 2 4 6.083 1.217 -6.771 7.275E-03
RAB5A chr3p24-p22 209089_at 5 2 6 0.419 0.240 -9.065 5.698E-04
RAF1 chr3p25 201244_s_at 3 2 9 0.555 0.389 -24.008 5.074E-04
SCN10A chr3p22-p21 208578_at 3 4 23 1.806 0.884 -4.253 8.107E-03
Table 4.b.: Genes/probes with CN gain (CN = 3 or 4)
ARHGAP5 chr14q12 217936_at 2 5 1 1.731 0.769 -4.809 8.159E-03
CYP11B1 chr8q21 214610_at 2 6 3 0.915 1.114 4.728 3.469E-03
NFATC4 chr14q11.2 205897_at 2 3 1 1.363 0.903 -11.692 2.823E-03
PAX9 chr14q12-q13 207059_at 2 5 1 0.898 0.319 -5.395 5.706E-03
PPFIA1 chr11q13.3 202066_at 7 2 12 7.524 2.448 -3.918 6.425E-03
TP63 chr3q28 211834_s_at 2 13 17 0.901 1.197 3.438 9.809E-03
TP63 chr3q28 211194_s_at 2 13 18 0.987 2.649 4.008 3.640E-03
*Sorted alphabetically by gene name
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Page 8 of 11every chromosome arm, indicating that it is a common
phenomenon.
The frequency of CNNLOH observed here in ESCC
was much less than has been reported in other cancers
[3-19]. For example, in colon cancer and basal cell carci-
noma nearly all LOH was associated with copy number
neutral regions [3,10]. In general, CNNLOH occurs with
variable frequency in different genomic regions in
tumors of different origin. There are several differences
between the study reported here and previous studies
which likely influenced the results. First, DNA from
micro-dissected tumor and adjacent normal was used in
the present study, while either cancer DNA without
matched controls or cancer cell lines were used in most
other reported studies. Second, we examined LOH and
CN alterations using the same SNP array platform,
while other studies used SNPs for LOH and CGH arrays
for CN analyses. Third, the criteria for identifying LOH
differed among the studies reported. Finally, the types of
cancers studied previously differ from the present study
which is the first report of CNNLOH in ESCC.
In previous LOH studies, we reported high-frequency
LOH on several chromosome arms, including 3p, 4p,
4q, 9p, 9q, 13q, 17p, and 17q [23,26,27]. By integrating
LOH and CN alteration data in the present study, we
can now say that the LOH on 3p is primarily due to CN
loss LOH, while the LOH on the other seven chromo-
some arms is predominantly due to CNNLOH.
Our results showed that CNNLOH can change expres-
sion levels of genes in ESCC, either increasing or decreas-
ing them. We do not know why CNNLOH changes gene
expression, but one possibility is that the two alleles may
have different gene expression levels. For example, if
allele A expression is greater than allele B, the expression
level for the 3 genotypes would be ordered as AA > AB >
BB. CNNLOH with retention of two B alleles (genotype
BB) would then show lower expression than genotype
AB. Conversely, CNNLOH with loss of the allele B would
result in two copies of allele A and a higher level of
expression than that of AB cells. Another possibility is
that the two alleles have different expression due to dif-
ferent epigenetic states, with LOH resulting in copies
with two extreme epigenetic states. A third possibility is
that one allele harbors a mutation and subsequent LOH
leads to a homozygous mutant. Several studies have
shown that CNNLOH regions can harbor mutated genes.
For example, JAK2 V617F, FLT3-ITD, AML1/RUNX1,
WT1,a n dNPM1 mutations were all found in CNNLOH
regions in AML [15]. These various hypotheses merit
testing in the future.
The study design in the present study has several
important features: (i) we compared CN status between
DNA from germ-line and micro-dissected adjacent nor-
mal tissue; (ii) we used micro-dissected DNA from
tumor tissue; (iii) we assessed both LOH and CN altera-
tions simultaneously using the same array platform; and
(iv) we integrated complex DNA alterations and gene
expression data on a genome-wide level using both high
density SNP and expression arrays in the same cases. A
noteworthy weakness of our study is the relatively small
number of cases evaluated (including a particularly
small number of cases with both LOH and RNA expres-
sion data to evaluate, due in part to the 500K chip
mean heterozygosity of 27%), which limited our power
to detect significant differences in loci between LOH
and non-LOH groups. In addition, findings for ESCC
from this high-risk region may not be generalizable to
populations elsewhere in the world.
In summary, we investigated the distribution of com-
plex DNA alterations in ESCCs at the genome-wide
level and determined that CN neutral is the most com-
mon CN state in LOH, and that CNNLOH is a very
common phenomenon overall. Importantly, we also
showed that CNNLOH could alter the expression level
of genes affected in ESCC.
Conclusion
CNNLOH is a common phenomenon in many cancers,
including ESCC, and non-disjunction and/or somatic
recombination are the most likely mechanisms for its
occurrence. CNNLOH can result in changes in gene
expression which are functionally significant. Expression
differences in CNNLOH suggest that alleles are different
in terms of their gene expression potential, and that
these differences may result from differences in geno-
type and/or epigenetics.
Additional material
Additional file 1: Figure S1. Definition of LOH/CN blocks within a single
sample.
Additional file 2: Figure S2. The relationship between genes, Affymetrix
expression probesets, and SNPs.
Additional file 3: Table S1. Comparison of copy number alterations
between DNA from blood and microdissected normal tissue.
Additional file 4: Table S2. Copy number status of SNPs without LOH
by case (N = 30).
Additional file 5: Table S3. CN status of SNPs without LOH by
chromosome arm (N = 30 cases).
Additional file 6: Table S4. No. of genes matched on Affymetrix 500 K
SNP and U133A expression arrays.
Additional file 7: Table S5. Comparison of gene expression in copy
number neutral (CNN) genes with LOH and without LOH (normal) (N =
168 genes significantly differentially-expressed).
Abbreviations
SNP: single nucleotide polymorphism; ESCC: esophageal squamous cell
carcinoma; (CNNLOH): copy number neutral loss of heterozygosity; CN: copy
number.
Hu et al. BMC Genomics 2010, 11:576
http://www.biomedcentral.com/1471-2164/11/576
Page 9 of 11Acknowledgements
This research was supported by the Intramural Research Program of the NIH,
the National Cancer Institute, the Division of Cancer Epidemiology and
Genetics, and the Center for Cancer Research.
Author details
1Genetic Epidemiology Branch, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland, USA.
2Laboratory of Population Genetics, Center for Cancer Research, National
Cancer Institute, NIH, DHHS, Bethesda, Maryland, USA.
3Shanxi Cancer
Hospital, Taiyuan, Shanxi, 030013, PR China.
Authors’ contributions
NH, AMG, TD, and PRT designed, conducted, and supervised the field and
clinical studies; PRT obtained funding for the project; NH and CW designed
and performed the laboratory analyses; NH, RJC, HHY, and MPL conducted
the statistical analyses; NH and ML drafted the manuscript; NH, RJC, AMG,
PRT, and MPL conceptualized the data analyses and revised and edited the
manuscript. All authors read and approved the final manuscript.
Received: 28 February 2010 Accepted: 18 October 2010
Published: 18 October 2010
References
1. Huang J, Wei W, Zhang J, Liu G, Bignell GR, Stratton MR, et al: Whole
genome DNA copy number changes identified by high density
oligonucleotide arrays. Hum Genomics 2004, 1:287-299.
2. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, et al: High-
resolution analysis of DNA copy number using oligonucleotide
microarrays. Genome Res 2004, 14:287-295.
3. Teh MT, Blaydon D, Chaplin T, Foot NJ, Skoulakis S, Raghavan M, et al:
Genomewide single nucleotide polymorphism microarray mapping in
basal cell carcinomas unveils uniparental disomy as a key somatic event.
Cancer Res 2005, 65:8597-8603.
4. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, Skoulakis S,
et al: Association between acquired uniparental disomy and
homozygous gene mutation in acute myeloid leukemias. Cancer Res
2005, 65:9152-9154.
5. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ,
et al: Genome-wide single nucleotide polymorphism analysis reveals
frequent partial uniparental disomy due to somatic recombination in
acute myeloid leukemias. Cancer Res 2005, 65:375-378.
6. Langdon JA, Lamont JM, Scott DK, Dyer S, Prebble E, Bown N, et al:
Combined genome-wide allelotyping and copy number analysis identify
frequent genetic losses without copy number reduction in
medulloblastoma. Genes Chromosomes Cancer 2006, 45:47-60.
7. Stark M, Hayward N: Genome-wide loss of heterozygosity and copy
number analysis in melanoma using high-density single-nucleotide
polymorphism arrays. Cancer Res 2007, 67:2632-2642.
8. Ross CW, Ouillette PD, Saddler CM, Shedden KA, Malek SN: Comprehensive
analysis of copy number and allele status identifies multiple
chromosome defects underlying follicular lymphoma pathogenesis. Clin
Cancer Res 2007, 13:4777-4785.
9. Gaasenbeek M, Howarth K, Rowan AJ, Gorman PA, Jones A, Chaplin T, et al:
Combined array-comparative genomic hybridization and single-
nucleotide polymorphism-loss of heterozygosity analysis reveals
complex changes and multiple forms of chromosomal instability in
colorectal cancers. Cancer Res 2006, 66:3471-3479.
10. Andersen CL, Wiuf C, Kruhoffer M, Korsgaard M, Laurberg S, Orntoft TF:
Frequent occurrence of uniparental disomy in colorectal cancer.
Carcinogenesis 2007, 28:38-48.
11. van PM, Middeldorp A, Tops CM, van ER, van der Klift HM, Vasen HF, et al:
Genome-wide copy neutral LOH is infrequent in familial and sporadic
microsatellite unstable carcinomas. Fam Cancer 2008, 7:319-330.
12. Lo KC, Bailey D, Burkhardt T, Gardina P, Turpaz Y, Cowell JK:
Comprehensive analysis of loss of heterozygosity events in glioblastoma
using the 100K SNP mapping arrays and comparison with copy number
abnormalities defined by BAC array comparative genomic hybridization.
Genes Chromosomes Cancer 2008, 47:221-237.
13. Kuga D, Mizoguchi M, Guan Y, Hata N, Yoshimoto K, Shono T, et al:
Prevalence of copy-number neutral LOH in glioblastomas revealed by
genomewide analysis of laser-microdissected tissues. Neuro Oncol 2008,
10:995-1003.
14. Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M, et al:
Allelic imbalances and microdeletions affecting the PTPRD gene in
cutaneous squamous cell carcinomas detected using single nucleotide
polymorphism microarray analysis. Genes Chromosomes Cancer 2007,
46:661-669.
15. Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, Sanada M, et al:
Hidden abnormalities and novel classification of t(15;17) acute
promyelocytic leukemia (APL) based on genomic alterations. Blood 2009,
113:1741-1748.
16. Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, et al: A
comprehensive analysis of the CDKN2A gene in childhood acute
lymphoblastic leukemia reveals genomic deletion, copy number neutral
loss of heterozygosity, and association with specific cytogenetic
subgroups. Blood 2009, 113:100-107.
17. Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL,
et al: Are there any more ovarian tumor suppressor genes? A new
perspective using ultra high-resolution copy number and loss of
heterozygosity analysis. Genes Chromosomes Cancer 2009, 48:931-942.
18. Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI,
et al: Genome-wide copy number analysis in esophageal
adenocarcinoma using high-density single-nucleotide polymorphism
arrays. Cancer Res 2008, 68:4163-4172.
19. O’Keefe C, McDevitt MA, Maciejewski JP: Copy neutral loss of
heterozygosity: a novel chromosomal lesion in myeloid malignancies.
Blood 2010, 115:2731-2739.
20. Li JY: Epidemiology of esophageal cancer in China. Natl Cancer Inst
Monogr 1982, 62:113-120.
21. Qiao YL, Hou J, Yang L, He YT, Liu YY, Li LD, et al: [The trends and
preventive strategies of esophageal cancer in high-risk areas of Taihang
Mountains, China]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001, 23:10-14.
22. Hu N, Roth MJ, Emmert-Buck MR, Tang ZZ, Polymeropolous M, Wang QH,
et al: Allelic loss in esophageal squamous cell carcinoma patients with
and without family history of upper gastrointestinal tract cancer. Clin
Cancer Res 1999, 5:3476-3482.
23. Hu N, Roth MJ, Polymeropolous M, Tang ZZ, Emmert-Buck MR, Wang QH,
et al: Identification of novel regions of allelic loss from a genomewide
scan of esophageal squamous-cell carcinoma in a high-risk Chinese
population. Genes Chromosomes Cancer 2000, 27:217-228.
24. Huang J, Hu N, Goldstein AM, Emmert-Buck MR, Tang ZZ, Roth MJ, et al:
High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal
squamous cell carcinomas from a high incidence area in northern China.
Carcinogenesis 2000, 21:2019-2026.
25. Hu N, Su H, Li WJ, Giffen C, Goldstein AM, Hu Y, et al: Allelotyping of
esophageal squamous-cell carcinoma on chromosome 13 defines
deletions related to family history. Genes Chromosomes Cancer 2005,
44:271-278.
26. Hu N, Wang C, Hu Y, Yang HH, Kong LH, Lu N, et al: Genome-wide loss of
heterozygosity and copy number alteration in esophageal squamous
cell carcinoma using the Affymetrix GeneChip Mapping 10 K array. BMC
Genomics 2006, 7:299.
27. Hu N, Wang C, Ng D, Clifford R, Yang HH, Tang ZZ, et al: Genomic
characterization of esophageal squamous cell carcinoma from a high-
risk population in China. Cancer Res 2009, 69:5908-5917.
28. Hu N, Flaig MJ, Su H, Shou JZ, Roth MJ, Li WJ, et al: Comprehensive
characterization of annexin I alterations in esophageal squamous cell
carcinoma. Clin Cancer Res 2004, 10:6013-6022.
29. Li G, Hu N, Goldstein AM, Tang ZZ, Roth MJ, Wang QH, et al: Allelic loss on
chromosome bands 13q11-q13 in esophageal squamous cell carcinoma.
Genes Chromosomes Cancer 2001, 31:390-397.
30. Hu N, Li G, Li WJ, Wang C, Goldstein AM, Tang ZZ, et al: Infrequent
mutation in the BRCA2 gene in esophageal squamous cell carcinoma.
Clin Cancer Res 2002, 8:1121-1126.
31. Ng D, Hu N, Hu Y, Wang C, Giffen C, Tang ZZ, et al: Replication of a
genome-wide case-control study of esophageal squamous cell
carcinoma. Int J Cancer 2008, 123:1610-1615.
32. Gao Y, Hu N, Han X, Giffen C, Ding T, Goldstein A, et al: Family history of
cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC
Cancer 2009, 9:269.
Hu et al. BMC Genomics 2010, 11:576
http://www.biomedcentral.com/1471-2164/11/576
Page 10 of 1133. Gao Y, Hu N, Han X, Giffen C, Ding T, Goldstein AM, et al: Jasmine tea
consumption and upper gastrointestinal cancer in China. Cancer Causes
Control 2009, 20:1997-2007.
34. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z,
Goldstein SR, et al: Laser capture microdissection. Science 1996,
274:998-1001.
35. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U,
et al: Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
36. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of
normalization methods for high density oligonucleotide array data
based on variance and bias. Bioinformatics 2003, 19:185-193.
doi:10.1186/1471-2164-11-576
Cite this article as: Hu et al.: Genome wide analysis of DNA copy
number neutral loss of heterozygosity (CNNLOH) and its relation to
gene expression in esophageal squamous cell carcinoma. BMC Genomics
2010 11:576.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hu et al. BMC Genomics 2010, 11:576
http://www.biomedcentral.com/1471-2164/11/576
Page 11 of 11